ClinicalTrials.gg
Not yet recruitingNCT07758491Updated Sep 2, 2026

A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma

A Phase 1/2 interventional study of FG-M131 and FG-M131 in PTCL, TRBC1 ADC and CTCL, sponsored by FutureGen Biopharmaceutical (Beijing) Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

FG-M131 for injection is an antibody-drug conjugate (ADC) targeting the T-cell receptor beta chain constant region 1 (TRBC1). TRBC1 is a subunit of the αβ T-cell receptor (TCR) complex. Targeting TRBC1 can eliminate TRBC1-positive malignant T cells while sparing TRBC2-positive normal T cells, providing a novel strategy for the treatment of T-cell malignancies.

This study is a multicenter, open-label Phase I/II clinical trial in patients with TRBC1-positive relapsed/refractory peripheral T-cell lymphoma, designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary antitumor activity of FG-M131 for injection in this patient population. The study consists of a Phase I dose-escalation stage and a Phase IIa cohort-expansion stage.

02

Conditions studied

  • PTCL
  • TRBC1 ADC
  • CTCL

Keywords

  • PTCL
  • TRBC1 ADC
  • CTCL
03

In context

Lead sponsor

FutureGen Biopharmaceutical (Beijing) Co., Ltd is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily sign the form, understand the study, are willing to comply with and have the ability to complete all trial procedures;
  • Age 18-75 years (inclusive), any gender;
  • and/or cytologically confirmed peripheral T-cell lymphoma or cutaneous T-cell lymphoma;
  • lymphoma after at least one ;
  • Able to provide tumor tissue specimens;
  • performance status of 0 or 1;
  • Expected survival ≥3 months;
  • Have at least one measurable tumor lesion;
  • Adequate cardiac, bone marrow, liver, renal function;

Exclusion criteria

Exclusion Criteria:

  • Have received a within 3 months prior to the first dose;
  • Have received radiotherapy within 4 weeks prior to the first dose;
  • Have received other anti-tumor drug therapy within 3 weeks or within 5 half-lives of the anti-tumor drug prior to the first dose;
  • Have undergone major surgery within 4 weeks prior to the first dose;
  • Have previously received any therapy targeting the TRBC1 antigen or any antibody-drug conjugate with MMAE payload;
  • Have received stem cell transplantation within 3 months prior to the first dose;
  • Have previously received allogeneic stem cell transplantation;
  • Have a history of other within 5 years prior to the first dose;
  • Have received high-dose systemic vitamin A therapy (daily dose >15,000 IU [i.e., 5,000 mcg]) within 3 weeks prior to the first dose of study drug;
  • Have any condition requiring systemic treatment with (>20 mg/day prednisone or equivalent) or other agents within 14 days prior to the first dose;
  • Have received oral retinoid drugs for any indication within 3 weeks prior to the first dose;
  • Have adverse reactions from prior treatments that have not recovered to v5.0 Grade ≤1 (excluding alopecia and anemia) prior to the first dose;
  • Presence or history of central nervous system lymphoma, , or spinal cord compression;
  • Have a history of severe allergic reactions or are allergic to the drug;
  • Have experienced a cardiac disease within 6 months before the first dose;
  • Have uncontrolled systemic diseases assessed by the investigator, including diabetes, hypertension, pulmonary fibrosis, interstitial lung disease, etc.;
  • Known history of or chronic active ;
  • Clinically uncontrolled diseases such as diabetes mellitus, thyroid disease, or other severe systemic diseases requiring systemic treatment;
  • Active or progressive infection requiring systemic therapy within 2 weeks prior to the first dose;
  • Known or suspected active disease requiring systemic therapy within 2 years prior to the first dose;
  • Are pregnant or breastfeeding;
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    FG-M131 Dose Escalation Cohort

    Dose Escalation Cohort Eight dose levels of FG-M131 will be tested according to an accelerated titration method followed by a adaptive BOIN design.

    Drug: FG-M131

  • Experimental
    FG-M131 Dose Expansion Cohort

    Once the effective dose has been determined, 2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.

    Drug: FG-M131

Interventions

  • DrugFG-M131

    Accelerated titration method, IV infusion Q3W; Adaptive BOIN design, IV infusion Q3W. (21-day cycles)

  • DrugFG-M131

    1\~2 dose levels of FG-M131 will be tested according to the result from dose escalation stage

06

What researchers measure

Primary outcomes

  1. Safety assessed by Adverse Events (AEs)

    Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: Up to 24 months

  2. Maximum Tolerated Dose (MTD)

    MTD

    Time frame: 21 days

  3. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by investigator evaluation.

    Time frame: Up to 24 months

  4. Complete Response Rate (CRR)

    CRR is defined as the proportion of participants who have a best overall response of Complete Response (CR) as assessed by investigator evaluation

    Time frame: Up to 24 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the duration from randomization to the first imaging confirmation of progressive disease by investigator evaluation or death due to any cause (whichever occurs first).

    Time frame: Up to 24 months

  2. Duration Of Response (DOR)

    DOR is defined as the time from the date of the first response (CR/PR) until the date of progressive disease as assessed by investigator evaluation or death due to any cause (whichever occurs first).

    Time frame: Up to 24 months

  3. Overall Survival (OS)

    OS is defined as the time from randomization to deathdue to any cause.

    Time frame: Up to 24 months

  4. Maximum measured plasma concentration of FG-M131

    Cmax

    Time frame: Up to 24 months

  5. Time to maximum plasma concentration of FG-M131

    Tmax

    Time frame: Up to 24 months

  6. Half-life of FG-M131

    T1/2

    Time frame: Up to 24 months

  7. ADA

    Incidence of anti-FG-M131 antibody and/or neutralizing antibody positivity

    Time frame: Up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jan 2031, 53 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Aug 11, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Jan 2031
CompletionEst.
Apr 2031
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07758491
Responsible party
Sponsor
First posted
Aug 11, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Jan 2031 (estimated)
Completion
Apr 2031 (estimated)
Last update
Sep 2, 2026

Study contacts

Zhaoyu Jin
Contact
pr@futuregenbiopharm.com
+8610-60709130

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion